NCT/Study#

BND-22-001

?A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors

?A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors

DISEASE GROUP:
Phase 1
current phase:
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: